ValuEngine lowered shares of GlaxoSmithKline (NYSE:GSK) from a buy rating to a hold rating in a research report released on Friday morning.

Several other research analysts also recently weighed in on GSK. JPMorgan Chase & Co. reiterated a neutral rating on shares of GlaxoSmithKline in a research note on Tuesday, October 24th. Zacks Investment Research downgraded GlaxoSmithKline from a buy rating to a hold rating in a research note on Wednesday, January 10th. Investec downgraded GlaxoSmithKline from a buy rating to a hold rating in a research note on Monday, November 6th. TheStreet upgraded GlaxoSmithKline from a c+ rating to a b rating in a research note on Wednesday, October 25th. Finally, Bank of America downgraded GlaxoSmithKline from a buy rating to a neutral rating in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline has an average rating of Hold and an average price target of $38.57.

GlaxoSmithKline (GSK) opened at $36.48 on Friday. The stock has a market capitalization of $91,969.94, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 2.30 and a beta of 0.98. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53.

Institutional investors and hedge funds have recently modified their holdings of the stock. Field & Main Bank purchased a new stake in GlaxoSmithKline during the 4th quarter worth about $132,000. Wealthcare Advisory Partners LLC lifted its holdings in GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after purchasing an additional 3,351 shares in the last quarter. FTB Advisors Inc. lifted its holdings in GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock worth $146,000 after purchasing an additional 539 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock worth $162,000 after purchasing an additional 148 shares in the last quarter. Finally, Advisory Services Network LLC lifted its holdings in GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock worth $175,000 after purchasing an additional 788 shares in the last quarter. 9.66% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Downgrades GlaxoSmithKline (GSK) to Hold” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2018/02/05/valuengine-downgrades-glaxosmithkline-gsk-to-hold.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.